Treatment preferences in people with haemophilia A or caregivers of people with haemophilia A: A discrete choice experiment

Introduction The standard of care for people with haemophilia A (PwHA) is regular prophylactic therapy with Factor VIII. However, very little is known about the treatment preferences of PwHA with and without inhibitors, or their caregivers, when presented with the choice between intravenous and subc...

Full description

Saved in:
Bibliographic Details
Published in:Haemophilia : the official journal of the World Federation of Hemophilia 2020-08, Vol.26 (S5), p.30-40
Main Authors: Fifer, Simon, Kerr, Annette M., Parken, Claire, Hamrosi, Kim, Eid, Samantha
Format: Article
Language:English
Subjects:
bypassing agents
caregiver
Caregivers
Coagulation factors
discrete choice
Factor VIII
Factor VIII deficiency
haemophilia A
Hemophilia
Intravenous administration
patient preference
Side effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction The standard of care for people with haemophilia A (PwHA) is regular prophylactic therapy with Factor VIII. However, very little is known about the treatment preferences of PwHA with and without inhibitors, or their caregivers, when presented with the choice between intravenous and subcutaneous prophylactic treatments with different modes of action, side effect risk and frequency of administration. Methods We conducted a discrete choice experiment to assess the preferences of PwHA or their caregivers. The survey was conducted in Australia, New Zealand, Canada, France, Italy and the United Kingdom. Results There were 56 respondents. The majority of PwHA had hereditary HA (78%) rather than spontaneous HA (22%). Most PwHA were diagnosed when they were under 12 months old (65%). The model identified two segments based on treatment preferences. There is heterogeneity between PwHA in their treatment preferences. People with and without inhibitors prefer to receive treatment via a subcutaneous injection compared to an intravenous infusion. However, for PwHA, efficacy is key; they value a reduction in the annual bleed rate. For those without inhibitors, this also includes a reduction in the risk of developing inhibitors. The side effect risk, administration risk and storage requirements were prioritised differently in each segment. Conclusions Results from this study may inform decisions about the value of existing and new treatments for PwHA.
ISSN:1351-8216
1365-2516
DOI:10.1111/hae.14037